PEPG

PepGen Inc

2.36

Oct 30 • 3:59 PM ET -0.05 (-2.07%)

2.41

Aftermarket • 7:49 PM ET +0.05 (2.12%)

Healthcare Biotechnology USA Micro NASD

Peers: TRDA DYN DSGN WVE SRPT STOK SLDB EWTX IONS CAPR

| Held by: VTI VXF IBB IWC BUSM AVSC DFAS DXUV DFMC DFSU

Scroll to Statements

Index	-
Market Cap	163.45M
Enterprise Value	62.30M
Income	-71.94M
Sales	0.00M
Book/sh	1.73
Cash/sh	1.69
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	56
IPO	May 06, 2022

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.37
P/C	1.39
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	13.36
Current Ratio	13.36
Debt/Eq	0.13
LT Debt/Eq	0.11
Option/Short	Yes / Yes

EPS (ttm)	-1.31
EPS next Y	-1.11
EPS next Q	-0.27
EPS this Y	48.91%
EPS next Y	-2.14%
EPS next 5Y	21.56%
EPS past 3/5Y	10.01% -63.43%
Sales past 3/5Y	- -
EPS Y/Y TTM	56.00%
Sales Y/Y TTM	-
EPS Q/Q	63.49%
Sales Q/Q	-
Earnings	Aug 06 BMO
EPS/Sales Surpr.	8.61% -

Insider Own	10.77%
Insider Trans	-0.02%
Inst Own	71.85%
Inst Trans	-5.16%
ROA	-59.06%
ROE	-75.45%
ROIC	-54.34%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-6.37%
SMA50	-14.31%
SMA200	-22.22%
Trades

Shs Outstand	69.26M
Shs Float	61.80M
Short Float	6.16%
Short Ratio	4.09
Short Interest	3.80M
52W High	7.80 -69.74%
52W Low	1.31 80.15%
Volatility	7.71% 8.48%
ATR (14)	0.21
RSI (14)	42.01
Beta	2.01
Rel Volume	1.21
Avg Volume	931.44K
Volume	1,129,070

Perf Week	-6.35%
Perf Month	6.79%
Perf Quarter	25.53%
Perf Half Y	34.86%
Perf YTD	-63.75%
Perf Year	-47.90%
Perf 3Y	-57.93%
Perf 5Y	-
Perf 10Y	-
Recom	1.38
Target Price	10.19
Prev Close	2.41
Price	2.36
Change %	-2.07%

Consensus

Strong Buy

Avg. Price Target

$10.19

Implied Upside

+331.8%

Analysts4incl. previous ratings

Rating Distribution3 Buy · 0 Hold · 1 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Jun 16, 2026	Initiated	CCraig Hallum	Buy	$11	+366.1%
Sep 09, 2025	Initiated	GGuggenheim	Buy	$6	+154.2%
Dec 16, 2024	Downgrade	BBofA Securities	Neutral → Underperform	$3	+27.1%
Jul 31, 2024	Downgrade	BBofA Securities	Buy → Neutral	$12	+408.5%
Dec 21, 2022	Initiated	HH.C. Wainwright	Buy	$26	+1,001.7%

Aug-06-26 07:32AM	PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights (Business Wire) +21.72%
07:30AM	PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review (Business Wire)
May-21-26 07:00AM	PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program (Business Wire) +6.94%
May-12-26 04:05PM	PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights (Business Wire) +5.95%
Mar-30-26 04:05PM	PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data (Business Wire) -6.42% -58.16%
05:59AM	Loading…
Mar-05-26 05:59AM	PepGen muscular dystrophy drug gets surprise hold from FDA (BioPharma Dive) -18.57%
04:30AM	FDA Places Partial Hold On PepGen's Myotonic Dystrophy Drug Trial (Benzinga)
Mar-04-26 04:05PM	PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights (Business Wire) +5.30%
04:03PM	PepGen Announces Regulatory Updates on FREEDOM2 (Business Wire)
Mar-03-26 07:00AM	PepGen to Participate in the Leerink Global Healthcare Conference (Business Wire)
Dec-10-25 09:55AM	How Much Upside is Left in PepGen (PEPG)? Wall Street Analysts Think 75.44% (Zacks)
Dec-09-25 07:00AM	PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Business and Legal Officer (Business Wire)
Dec-08-25 07:00AM	PepGen Appoints Joseph Vittiglio, Esq., as Chief Business and Legal Officer (Business Wire)
Nov-25-25 01:08PM	Sarepta's Stock Rises on Positive Updates on DM1 Therapy (Zacks)
Nov-12-25 07:05AM	PepGen Announces Issuance of U.S. Patent for Proprietary PGN-EDODM1 Molecule (Business Wire) +10.32%
07:00AM	Loading…
07:00AM	PepGen Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights (Business Wire)
Nov-03-25 07:00AM	PepGen to Participate in Upcoming Investor Conferences (Business Wire)
Oct-26-25 06:06AM	BofA Lifts PepGen (PEPG) PT to $3 on Positive DM1 Data Despite Underperform Rating (Insider Monkey)
Oct-02-25 07:00AM	PepGen Announces Oral Presentations at the 30th Annual International Congress of the World Muscle Society (Business Wire) +7.86%
Sep-30-25 11:50AM	PepGen Inc. (PEPG) Rating Upgraded With 135% Upside on FREEDOM Data (Insider Monkey)
Sep-26-25 04:01PM	PepGen Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares (Business Wire) -13.78% -8.48%
08:06AM	PepGen (PEPG) Skyrockets 121% on Stellar Experimental Treatment Trial Results (Insider Monkey)
07:31AM	PepGens stock up 120% on DM1 trial success (Clinical Trials Arena)
Sep-25-25 09:46AM	PepGen Reports Highest Splicing Correction In Dystrophy Patients, Stock Doubles (Benzinga) +121.05%
Sep-24-25 10:51PM	PepGen Announces Pricing of $100 Million Public Offering (Business Wire) +36.41%
04:21PM	PepGen Announces Proposed Public Offering (Business Wire)
04:16PM	PepGen Announces Highest Mean Splicing Correction Reported in DM1 Patients (Business Wire)
Aug-07-25 08:00AM	PepGen Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights (Business Wire) -13.14%
Aug-05-25 08:45AM	PepGen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before August 8, 2025 to Discuss Your Rights - PEPG (PR Newswire)
Aug-01-25 09:00AM	PepGen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before August 8, 2025 to Discuss Your Rights - PEPG (PR Newswire)
04:17PM	Loading…
Jul-29-25 04:17PM	Investors in PepGen Inc. (PEPG): Protect Your Rights - Contact Levi & Korsinsky Before August 8, 2025 (Newsfile)
May-30-25 09:00AM	PepGen price target lowered to $1 from $3 at BofA (TipRanks) -12.57%
08:55AM	PepGen to discontinue DMD programs after PGN-EDO51 did not achieve target (TipRanks)
06:36AM	Keros lays off nearly half its staff; Astellas buys into a China biotechs ADC (BioPharma Dive)
May-29-25 12:01AM	PepGen Inc. (PEPG) Halts DMD Program After Trial Miss; Shifts Focus to DM1 (Insider Monkey) +5.70%
May-28-25 04:05PM	PepGen to Focus on Development of Promising DM1 Program Following 10 mg/kg PGN-EDO51 Update (Business Wire) +7.48%
May-20-25 07:00AM	PepGen Appoints Kasra Kasraian, PhD, as Chief Technology Officer (Business Wire) +6.04%
May-08-25 08:00AM	PepGen Reports First Quarter 2025 Financial Results and Recent Corporate Highlights (Business Wire) +22.22%
Apr-02-25 04:05PM	PepGen to Present at the 24th Annual Needham Virtual Healthcare Conference (Business Wire) +11.45% -14.04%
Mar-31-25 04:05PM	PepGen Announces Appointment of Two New Directors to its Board (Business Wire) -5.07% -6.76%
Mar-28-25 09:00AM	RNA Biotechs: Current State And Outlook (Seeking Alpha) -8.07%
Mar-26-25 10:17AM	The Risk/Reward Of Avidity Biosciences And Its 2 Promising Programs (SeekingAlpha)
Mar-10-25 04:05PM	PepGen Announces Presentations at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference (Business Wire) -9.54% +19.90%
Mar-05-25 06:32AM	PepGen pauses Phase II DMD trial to review safety data (Clinical Trials Arena) +15.57%
Mar-04-25 08:05AM	PepGen to Participate in Upcoming Investor Conferences (Business Wire) -18.86%
08:00AM	PepGen Announces Update to Phase 2 CONNECT2-EDO51 Study in Patients with DMD (Business Wire)
Feb-25-25 07:38AM	PepGen reports positive initial data from Phase I DM1 therapy trial (Clinical Trials Arena) -25.33%
Feb-24-25 07:30AM	PepGen Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Corporate Highlights (Business Wire) +67.15%
07:00AM	PepGen Announces Positive Initial Results, Including Robust Splicing Correction, from Ongoing FREEDOM-DM1 Trial in Patients with DM1 (Business Wire)
Jan-31-25 07:21AM	PepGen price target lowered to $16 from $26 at H.C. Wainwright (TipRanks) -10.42%
Jan-29-25 04:05PM	PepGen Announces CONNECT Program Updates (Business Wire) -6.60% -21.74%
Jan-08-25 12:00PM	All You Need to Know About PepGen (PEPG) Rating Upgrade to Buy (Zacks)
Dec-16-24 08:00AM	PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy (Business Wire)
Nov-21-24 04:05PM	PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Senior Vice President, Clinical Development (Business Wire)
Nov-07-24 08:00AM	PepGen Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights (Business Wire) -21.70%
Nov-04-24 08:00AM	PepGen to Participate in Upcoming Investor Conferences (Business Wire)
Oct-08-24 07:00AM	PepGen Announces Presentations at the 29th Annual Congress of the World Muscle Society (Business Wire)
Sep-19-24 04:30PM	PepGen Announces Christopher Ashton, PhD, to Retire from its Board of Directors (Business Wire)
Aug-20-24 04:05PM	PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Vice President, Research & Development (Business Wire)
08:00AM	PepGen Appoints Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development (Business Wire)
Aug-08-24 08:00AM	PepGen Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights (Business Wire)
Aug-02-24 09:35AM	Down -39.63% in 4 Weeks, Here's Why You Should You Buy the Dip in PepGen (PEPG) (Zacks)
Jul-31-24 04:52AM	PepGen reports positive data from Phase II Duchenne muscular dystrophy trial (Clinical Trials Arena) -32.69%
Jul-30-24 04:02PM	PepGen Announces Positive Data from Low-Dose Cohort of PGN-EDO51 in Ongoing CONNECT1-EDO51 Phase 2 Clinical Trial for Treatment of Duchenne Muscular Dystrophy (Business Wire)
Jul-17-24 08:50AM	Recent Price Trend in PepGen (PEPG) is Your Friend, Here's Why (Zacks)
Jul-02-24 08:00AM	PepGen Appoints Afsaneh Mohebbi, Ph.D., as SVP, Portfolio and Program Management and Dave Borah, CFA, as SVP, Investor Relations and Corporate Communications (Business Wire) -8.88%
Jun-11-24 07:00AM	PepGen Announces Executive Team Promotions (Business Wire)
May-15-24 01:20PM	PepGen Q1 Loss Narrows (MT Newswires)
May-14-24 10:55PM	PEPG Stock Earnings: PepGen Beats EPS for Q1 2024 (InvestorPlace) +5.19%
04:02PM	PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Apr-12-24 01:30PM	Hedge Fund and Insider Trading News: ExodusPoint Capital Management, Bridgewater Associates, Glenview Capital Management, PepGen Inc. (PEPG), HCI Group Inc (HCI), and More (Insider Monkey)
Mar-13-24 04:05PM	PepGen to Participate in Upcoming Investor Conferences (GlobeNewswire)
07:00AM	PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Mar-12-24 09:55AM	Can PepGen, Inc. (PEPG) Climb 48.62% to Reach the Level Wall Street Analysts Expect? (Zacks)
Mar-11-24 12:00PM	PepGen, Inc. (PEPG) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Mar-06-24 11:54PM	PEPG Stock Earnings: PepGen Beats EPS for Q4 2023 (InvestorPlace) -7.34% -7.98%
04:01PM	PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments (GlobeNewswire)
Mar-04-24 07:00AM	PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Feb-29-24 03:02AM	14 Stocks With Heavy Insider Buying In 2024 (Insider Monkey) +14.68%
Feb-20-24 08:00AM	PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1 (GlobeNewswire)
Feb-07-24 07:30AM	PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock (GlobeNewswire) +17.63%
Jan-17-24 07:00AM	Mary Beth DeLena Joins PepGen as General Counsel and Secretary (GlobeNewswire)
Jan-08-24 07:00AM	PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping (GlobeNewswire)
Dec-18-23 08:00AM	PepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1) (GlobeNewswire) +6.03%
Nov-15-23 08:00AM	PepGen Announces Appointment of Howard Mayer, M.D. to Board of Directors (GlobeNewswire)
Nov-08-23 08:00AM	PepGen Reports Third Quarter 2023 Financial Results and Recent Corporate Developments (GlobeNewswire) -10.40%
Oct-12-23 07:00AM	PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1) (GlobeNewswire) +7.22%
Sep-27-23 04:16PM	PepGen Announces Upcoming Presentations at the 28th Annual Congress of the World Muscle Society and the World Congress of Neurology (GlobeNewswire)
Sep-06-23 04:05PM	PepGen Inc. Announces Clearance of CTA by Health Canada to Begin the FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 in Patients with Myotonic Dystrophy Type 1 (GlobeNewswire)
08:00AM	PepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting the Companys Enhanced Delivery Oligonucleotide Platform and PGN-EDODM1 Program at Two Medical Conferences (GlobeNewswire)
Sep-01-23 08:00AM	PepGen Announces Presentations at the 2023 Myotonic Dystrophy Foundation Annual Conference, Ottawa Neuromuscular Disease Meeting, and H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-08-23 08:15AM	PepGen Reports Second Quarter 2023 Financial Results and Recent Corporate Developments (GlobeNewswire)
Jun-13-23 04:05PM	PepGen Inc. Provides Update on Planned Initiation of Phase 1 Study of PGN-EDODM1 in Myotonic Dystrophy Type 1 (GlobeNewswire) +10.87% -7.99%
May-31-23 11:44AM	PepGen (PEPG) Down on Clinical Hold for DM1 Candidate (Zacks) -5.07%
May-30-23 04:05PM	PepGen Inc. Announces Clinical Hold in the U.S. on IND Application to Initiate a Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1) (GlobeNewswire)
May-18-23 07:00AM	PepGen Announces Clearance by Health Canada of CTA for PGN-EDO51 to Begin the Phase 2 Clinical Trial, CONNECT1-EDO51, for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
May-11-23 07:00AM	PepGen Reports First Quarter 2023 Financial Results and Recent Corporate Developments (GlobeNewswire)
May-04-23 08:00AM	PepGen to Participate in the Bank of America Securities 2023 Healthcare Conference (GlobeNewswire)
Apr-17-23 08:00AM	PepGen Announces Upcoming Data Presentations at the 2023 American Academy of Neurology Annual Meeting (GlobeNewswire) +23.09%
Apr-13-23 04:05PM	PepGen to Participate in the 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire) +6.07% -10.09%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kasraian Kasra	Chief Technical Officer	May 21 '26	Sale	1.41	1,233	1,739	50,074	May 26 04:43 PM
STRECK PAUL	EVP, Head of R&D	Mar 04 '26	Sale	6.23	1,879	11,709	76,226	Mar 06 04:14 PM
Donnelly Noel	Chief Financial Officer	Mar 04 '26	Sale	6.23	2,084	12,988	111,603	Mar 06 04:12 PM
McArthur James G	President and CEO	Mar 04 '26	Sale	6.23	5,275	32,876	296,326	Mar 06 04:09 PM

PepGen Inc. develops oligonucleotide therapies. It is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. The company was founded on November 9, 2020 and is headquartered in Boston, MA.

PresidentDr. James G. McArthur Ph.D.

Chief Financial OfficerMr. Noel P. Donnelly M.B.A.

J.D.Mr. Joseph D. Vittiglio Esq.

Chief Technical OfficerDr. Kasra Kasraian Ph.D.

Senior Vice President of HR & AdministrationMs. Emiko Bryant

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PEPG

PepGen Inc

Upgrade your Finviz experience